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IMPORTANCE Large-scale neuroimaging studies have revealed group differences in cortical
thickness across many psychiatric disorders. The underlying neurobiology behind these
differences is not well understood.
OBJECTIVE To determine neurobiologic correlates of group differences in cortical thickness
between cases and controls in 6 disorders: attention-deficit/hyperactivity disorder (ADHD),
autism spectrum disorder (ASD), bipolar disorder (BD), major depressive disorder (MDD),
obsessive-compulsive disorder (OCD), and schizophrenia.
DESIGN, SETTING, AND PARTICIPANTS Profiles of group differences in cortical thickness
between cases and controls were generated using T1-weighted magnetic resonance images.
Similarity between interregional profiles of cell-specific gene expression and those in the
group differences in cortical thickness were investigated in each disorder. Next, principal
component analysis was used to reveal a shared profile of group difference in thickness
across the disorders. Analysis for gene coexpression, clustering, and enrichment for genes
associated with these disorders were conducted. Data analysis was conducted between
June and December 2019. The analysis included 145 cohorts across 6 psychiatric disorders
drawn from the ENIGMA consortium. The numbers of cases and controls in each of the
6 disorders were as follows: ADHD: 1814 and 1602; ASD: 1748 and 1770; BD: 1547 and 3405;
MDD: 2658 and 3572; OCD: 2266 and 2007; and schizophrenia: 2688 and 3244.
MAIN OUTCOMES AND MEASURES Interregional profiles of group difference in cortical
thickness between cases and controls.
RESULTS A total of 12 721 cases and 15 600 controls, ranging from ages 2 to 89 years, were
included in this study. Interregional profiles of group differences in cortical thickness for each
of the 6 psychiatric disorders were associated with profiles of gene expression specific to
pyramidal (CA1) cells, astrocytes (except for BD), and microglia (except for OCD); collectively,
gene-expression profiles of the 3 cell types explain between 25% and 54% of variance in
interregional profiles of group differences in cortical thickness. Principal component analysis
revealed a shared profile of difference in cortical thickness across the 6 disorders (48%
variance explained); interregional profile of this principal component 1 was associated with
that of the pyramidal-cell gene expression (explaining 56% of interregional variation).
Coexpression analyses of these genes revealed 2 clusters: (1) a prenatal cluster enriched with
genes involved in neurodevelopmental (axon guidance) processes and (2) a postnatal cluster
enriched with genes involved in synaptic activity and plasticity-related processes. These
clusters were enriched with genes associated with all 6 psychiatric disorders.
CONCLUSIONS AND RELEVANCE In this study, shared neurobiologic processes were associated
with differences in cortical thickness across multiple psychiatric disorders. These processes
implicate a common role of prenatal development and postnatal functioning of the cerebral
cortex in these disorders.
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T he advancement of large-scale magnetic resonanceimaging (MRI) studies has enabled systematic investi-gations of cortical morphology, such as cortical thick-
ness and surface area, across a variety of psychiatric disorders.
In particular, the Enhancing Neuroimaging Genetics through
Meta-Analysis (ENIGMA) Consortium has conducted some of
the largest MRI studies characterizing group differences be-
tween patients (cases) and control individuals in the cerebral
cortex for a number of disorders, including attention-deficit/
hyperactivity disorder (ADHD),1 autism spectrum disorder
(ASD),2 bipolar disorder (BD),3 major depressive disorder
(MDD),4 obsessive-compulsive disorder (OCD),5 and
schizophrenia.6 Nonetheless, the neurobiology underlying these
MRI-derived macroscopic features is not well understood.
As identified in postmortem studies, there are subtle differ-
encesinthecellularcompositionofthecerebralcortexofpatients
diagnosed as having various psychiatric disorders (vs controls)
such as the density of neurons and/or glial cells and the extent
of dendritic arborization.7 Mostly lower neuronal density
and/or neuronal size have been documented in ASD,8 BD,9
MDD,10,11OCD,12 and schizophrenia.13-15 Similar alterations in the
density of glial cells (astrocytes, microglia, or oligodendrocytes)
have been observed in ASD,8 BD,9 MDD,10,11 and schizophrenia.16
SeveralMRIstudieshavedemonstrateddistinctinterregional
profiles of group differences in cortical thickness across the
34 regions of the Desikan-Killiany atlas.17 We use the word
profile to refer to interregional (spatial) variations in a measure,
such as cortical thickness, across the cerebral cortex. Lower
cortical thickness in temporal regions in cases (vs controls) is
a common feature across ADHD, ASD, BD, MDD, OCD, and
schizophrenia1-6,18; a 2019 report of the ENIGMA cohorts19
showed cross-disorder correlations among disorders. Likewise,
large-scale genome-wide association studies (GWAS) identify
shared genetic architecture among these psychiatric disorders.20
To our knowledge, no studies have investigated system-
atically the association between microscopic ex vivo histol-
ogy and macroscopic in vivo differences in cortical thickness
across psychiatric disorders. This is required to facilitate our
understanding of MRI-derived measures in a neurobiologic
context as well as the usefulness of MRI for tracking of clini-
cal progression of disorders and their treatment.
Here, we generate profiles of group differences in cortical
thickness between cases and controls for ADHD, ASD, BD, MDD,
OCD, and schizophrenia using an identical linear-modeling ap-
proach executed in each participating cohort. Next, we use a
virtual histology approach whereby interregional profiles of
cell-specific gene expression are correlated across the 34 cor-
tical regions,17 with interregional profiles of group differ-
ences in cortical thickness. Through a series of bioinformatic
approaches, we then identify shared cellular correlates across
the 6 psychiatric disorders.
Methods
Group Differences in Cortical Thickness
T1-weighted MRI scans were acquired in 145 cohorts partici-
pating in the ENIGMA Consortium with varying MRI field
strength and vendors. Details regarding MRI acquisition and
sample demographics are found in eTable 1 and eTable 2 in the
Supplement. FreeSurfer cortical reconstruction (several ver-
sions) was used to derive measures of cortical thickness in
34 regions (per hemisphere), as segmented using the Desikan-
Killiany atlas.17,21 Quality control was conducted by contrib-
uting cohorts, following standardized ENIGMA protocols
(http://enigma.ini.usc.edu/protocols/imaging-protocols/).
Individual ENIGMA groups performed multiple linear
regression analyses in their respective cohorts, which modeled
cortical thickness of each region, separately, as a function of
diagnosis (eg, ADHD), age, age squared, sex, and site-specific
covariates (eg, MR scanner). Individual cohorts obtained
approval from local institutional ethics boards, and informed
consent was obtained from study participants or their
guardians. An inverse variance-weighted random-effects model
from the “metafor” R package (The R Foundation) was used
to generate meta-analytic profiles of group differences across
the 34 regions for each disorder.22 This report is an analysis of
shared data in the ENIGMA consortium rather than existing
literature.
Magnetic Resonance Imaging–Derived Similarity
and Genetic Similarity
This analysis was carried out to evaluate similarity in pair-
wise correlations in interregional profiles of group differ-
ences in cortical thickness and corresponding pairwise corre-
lations in genome-wide genetic architecture, described in the
eMethods in the Supplement. Group differences in cortical
thickness were first correlated across psychiatric disorders
with a biweight midcorrelation using R package WGCNA
(rationale in the eMethods in the Supplement).23 Genetic cor-
relations between psychiatric disorders were obtained from
the Brainstorm consortium.20 The similarity of the group
differences in cortical thickness and genetic cross-disorder
correlation matrices was tested for significance using Mantel
test from the “vegan” R package.24,25
Key Points
Question What are the neurobiologic underpinnings of group
differences in cortical thickness in various psychiatric disorders?
Findings In this consortium analysis of data from 145 cohorts,
regions of the cerebral cortex with greater expression of genes
specific to pyramidal (CA1) cells were also regions with greater
case-control group differences in cortical thickness in all
6 disorders: attention-deficit/hyperactivity disorder, autism
spectrum disorder, bipolar disorder, major depressive disorder,
obsessive-compulsive disorder, and schizophrenia. There was a
common profile of group differences in cortical thickness shared
among these disorders, which was associated with the expression
of genes involved in neurodevelopmental processes (prenatally)
and processes underlying synaptic activity and plasticity
(postnatally).
Meaning There are shared neurobiologic and cellular mechanisms
associated with differences in cortical thickness across multiple
psychiatric disorders, implicating a common role of prenatal
development and postnatal functioning of the cerebral cortex.
Research Original Investigation Virtual Histology of Cortical Thickness and Shared Neurobiology in 6 Psychiatric Disorders
48 JAMA Psychiatry January 2021 Volume 78, Number 1 (Reprinted) jamapsychiatry.com
© 2020 American Medical Association. All rights reserved.
Virtual Histology
Virtual histology is an approach that correlates, across space,
an MRI-derived profile, such as an interregional profile of group
differences in cortical thickness, with interregional profiles of
cell-specific gene expression.26,27 As described previously,
gene-expression data from the Allen Human Brain Atlas (AHBA;
6 donors, aged 24-57 years) were first mapped to the 34 re-
gions of the Desikan-Killiany atlas.28,29 To ensure similarity of
interregional profiles in gene expression across donors, and
across the life span, we applied a conservative 2-stage filter-
ing process. First, a donor-to-median correlation in the AHBA
was used to retain only genes whose profiles were consistent
among the 6 donors (retaining 8216 of 20 737 genes present in
AHBA). Second, the genes passing stage 1 were filtered based
on interregional profile similarity with an independent atlas
of gene expression, namely BrainSpan (retaining 2511 of 8216
genes; see eMethods in the Supplement for additional de-
tails). The final set of 2511 genes was used for analyses con-
ducted in this report. Next, single-cell RNA sequencing data
from the mouse hippocampus and S1 area of cerebral cortex
were used to categorize the 2511 genes as specific to 9 cell types
identified (CA1 pyramidal, S1 pyramidal, interneuron, astro-
cyte, microglia, oligodendrocyte, mural, endothelial, and
ependymal cells).30 Pyramidal cell types (CA1 and S1) were
labeled based on their anatomic origin, but the molecular char-
acteristics of these pyramidal cells, as indexed by gene expres-
sion, were not restricted to the brain regions in which these
2 types of pyramidal cells were found. The use of these pan-
els is analogous to a data reduction technique driven by neu-
robiologically relevant clustering (see the eMethods in the
Supplement for additional details). Interregional profiles of
cell-specific gene expression were then correlated across the
34 regions with MRI-derived profiles to generate a distribu-
tion of correlation coefficients for each of the cell types. This
distribution was then tested for significance using a resamp-
ling approach from 100 000 random samples. This analysis
was restricted to MRI profiles from the left hemisphere only
(owing to data availability in AHBA). In addition, we have
estimated the collective variance explained by cell types iden-
tified from virtual histology in interregional profiles of group
differences (see the eMethods in the Supplement).
Coexpression Analyses
Seed genes were defined by biweight midcorrelation be-
tween principal component 1 (PC1) profile (shared variance in
group differences in cortical thickness across the 6 disorders)
and cell-specific genes passing false discovery rate (FDR)–
corrected threshold; 2-sided P less than .05.31 For these analy-
ses, we harmonized gene-expression data from human cere-
bral cortex across 5 data sets (AHBA,29 BrainCloud,32 Brain
eQTL Almanac [Braineac],33 Genotype Tissue Expression
[GTEx],34 and BrainSpan).35 The curation of these 5 gene-
expression databases has been described previously and is pre-
sented in the eMethods in the Supplement.36,37 In total there
were 534 donors (aged 0-102 years) with gene-expression data
for 16 245 genes across all data sets. Coexpression analyses were
generated using linear mixed-effects models where gene
expression of each seed was modeled against other genes’ ex-
pression, with age and sex as fixed effects and donor identi-
fier as a random effect. The top 0.1% of positively coex-
pressed genes for each of the seed genes were used to construct
our coexpressed network panels.
Gene Trajectory Clustering
Coexpressed genes were clustered based on their temporal pat-
tern of gene expression using data from the BrainSpan atlas
(http://www.brainspan.org). This data set was chosen for the
gene trajectory clustering because it is the only one that
includes gene expression across prenatal and postnatal
developmental periods (42 donors, age range from 8
postconception weeks to age 40 years; 11 cortical regions).
Genes were clustered using mixed-effects models with
nonparametric smoothing spline fitting available in the
“TMixClust” R package (the eMethods and eTables 12-17 in
the Supplement for additional details).38
Gene Ontology, Kyoto Encyclopedia of Genes and Genomes,
and Psychiatric Disorder Enrichment Analysis
Gene ontology (GO) and Kyoto Encyclopedia of Genes and
Genomes pathway enrichment analysis were conducted using
the R package “clusterProfiler.”39 Gene ontology (biological pro-
cess ontology only) and Kyoto Encyclopedia of Genes and
Genomes terms with a minimum of 10 and a maximum of 500
genes were included in the analysis. Redundancy of GO terms
was removed based on similarity cutoff of 0.90. Enrichment
between coexpressed genes and genes associated with psy-
chiatric disorder were conducted using a hypergeometric test.
Genetic variants associated with psychiatric disorder were de-
rived from the DisGeNet database (http://www.disgenet.org).40
The background gene set for all of the aforementioned
enrichment test included 16 245 genes that were present in our
harmonized data set of gene expression for coexpression
analyses. P values were corrected using the FDR procedure.41
Results
Meta-analysis
We characterized meta-analytic profiles of group differences
in cortical thickness for each of the 6 disorders across the 34
regions of the cerebral cortex (Figure 1; eTables 3-8, eFigure 1
in the Supplement, left hemisphere only). In total, there were
12 721 cases and 15 600 controls contributing to these profiles
(eTable 2 in the Supplement). Across the disorders, interre-
gional variation in group differences of cortical thickness were
positively correlated between schizophrenia and ADHD, ASD,
BD, MDD, and OCD (Figure 2A). Overall, there was a general
trend of positive correlations (biweight midcorrelation, r >0)
of group differences across all 6 psychiatric disorders
(Figure 2A). Genetic correlations, as quantified by linkage dis-
equilibrium score regression, also showed a number of pair-
wise positive correlations among these psychiatric disorders,
in particular for schizophrenia (Figure 2B; reproduced using
data from the Brainstorm consortium).20 Cross-disorder simi-
larity of differences in cortical thickness (derived from MRI;
Figure 2A) was positively associated with cross-disorder
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genetic similarity (derived from GWAS; Figure 2B), explain-
ing 27% of variance (r = 0.52; Mantel P = .034, Pearson
P = .045).
Virtual Histology of Group Difference in Cortical Thickness
Interregional variation in the expression of genes specific to
pyramidal (CA1) cells was negatively associated with the
interregional profile of group differences in cortical thick-
ness in each of the 6 psychiatric disorders (−0.08 > r > −0.23;
FDR P value <.05, Figure 3; eTable 9, eFigure 2 in the Supple-
ment). Thus, regions with greater expression of pyramidal
(CA1)–specific genes showed greater differences in cortical
thickness between cases and controls. We also observed this
negative association with interregional profiles of expression
of genes specific to astrocytes and microglia in all 6 disorders
except BD (no correlation with astrocytes) and OCD (no cor-
Figure 1. Profiles of Group Differences in Cortical Thickness (Left Hemisphere Only) Between Cases and Controls
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Profiles of group differences in cortical thickness (left hemisphere only)
between cases and controls across the 6 psychiatric disorders investigated.
Group differences are adjusted for age, sex, and other site-specific variables.
Error bars represent 95% confidence intervals. Estimates less than zero
represent thinner cortex in cases as compared with controls.
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relation with microglia). Lastly, we observed a negative asso-
ciation between pyramidal (S1) specific expression and group
differences in thickness in BD only. The amount of interre-
gional variation in the group differences in cortical thickness
explained collectively by the gene-expression profiles is pre-
sented in eTable 18 in the Supplement.
Principal Component Analysis
Given the similarity of findings across the 6 disorders vis à vis
virtual histology, we used principal component analysis to
reduce the dimensions of the data (Figure 4A). The first prin-
cipal component (PC1) explained 48% of variation in group
differences of thickness profiles across the 6 disorders
(eFigure 3 in the Supplement). Principal component 1 was
positively correlated with each of disorder’s profiles (eFig-
ure 3C in the Supplement), and its interregional profile
was negatively associated with the interregional profiles of
pyramidal (CA1), astrocyte, and microglia-specific gene
expression (Figure 4B); regions with greater expression of
cell-specific genes showed greater differences in cortical
thickness between cases and controls. The amount of interre-
gional variation in the shared group difference in cortical
thickness explained by the gene-expression profiles is pre-
sented in eTable 18 in the Supplement.
Figure 2. Phenotypic and Genetic Similarity Between Psychiatric Disorders
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attention-deficit/hyperactivity disorder, ASD, autism spectrum disorder;
BD, bipolar disorder; MDD, major depressive disorder, OCD, obsessive-
compulsive disorder; SCZ, schizophrenia.
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Shared Neurobiology Across Disorders
To investigate the association between PC1 and CA1 pyrami-
dal specific genes, we used all CA1 genes associated signifi-
cantly (FDR significance threshold P < .05) with PC1 as
seed genes for coexpression analyses. Data from the AHBA,
BrainEAC, BrainSpan, BrainCloud, and GTEx were harmo-
nized to identify robust coexpression associations across the
genome (eFigures 4 and 5 in the Supplement). These PC1-CA1
coexpressed genes (412 genes) were clustered based on their
temporal pattern of expression using unsupervised nonpara-
metric mixed modeling. This analysis yielded 2 clusters: clus-
ter 1, which was upregulated during prenatal periods and down-
regulated in postnatal life, and cluster 2, which showed the
opposite developmental trajectory (Figure 5A). Gene ontol-
ogy enrichment analysis revealed involvement of neurode-
velopmental processes (axon development; fold enrichment
= 3.99; FDR P = 5.15 × 10-05) in the prenatal cluster (Figure 5B;
eFigure 6 in the Supplement) and involvement of synaptic sig-
naling/neurotransmission– and synaptic plasticity–related
terms (Fold enrichment, 4.70 and 4.56, respectively; FDR
P value = 5.11 × 10−09 and 2.31 × 10−03, respectively) in the post-
natal cluster (Figure 5C; eFigure 6 in the Supplement). Gene
enrichment analysis showed that the prenatal cluster is en-
riched in genes associated with ASD, BD, MDD, and schizo-
phrenia, while the postnatal cluster is enriched only in genes
associated with ADHD and schizophrenia (FDR P value <.05;
eFigure 7 in the Supplement). The entire coexpressed net-
work (ie, genes from both clusters) is enriched for all 6 disor-
ders, at varying levels of enrichment (eFigure 7 in the Supple-
ment). Finally, with the aid of laminar gene-expression data
from the developing human neocortex, we show that the pre-
natal cluster was upregulated in the cortical subplate zone and
cortical plate (area under the receiver operating curve, 0.68;
FDR P value = 2.35 × 10−15), while downregulated in the ven-
tricular zone (area under the receiver operating curve, 0.30;
FDR P value = 1.30 × 10−17; eFigure 8 and eTable 10 in the
Supplement). This held true for the postnatal cluster as well
(eFigure 8 and eTable 11 in the Supplement).
Figure 3. Virtual Histology of Group Differences in Cortical Thickness
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The analysis described previously was repeated for the as-
trocyte-specific and microglial-specific genes. Principal com-
ponent 1–astrocyte coexpressed genes (168 genes) were en-
riched in metabolic processes, such as amino acid transport
(Fold enrichment = 19.56; FDR P value = 2.09 × 10−03), as well
as enriched in genetic variants associated with BD and schizo-
phrenia (Fold enrichment = 2.50 and 1.82; FDR P value = .01
and .01, respectively; eFigure 9 in the Supplement). Principal
component 1–microglia coexpressed genes (118 genes) were en-
riched in immune-related processes (Fold enrichment = 11.93;
FDR P value = 1.7 × 10−08) and showed no enrichment with
genetic variants associated with any of the 6 psychiatric dis-
orders (eFigure 10 in the Supplement).
Discussion
We characterized robust interregional differences in cortical
thickness between cases and controls across the cerebral cor-
tex in 6 common psychiatric disorders, as done previously by
the individual working groups of the ENIGMA consortium.1-6,18
The interregional profiles presented in this report were gen-
erated using the same linear model (with the same covari-
ates) in each of the 145 participating cohorts and, as such,
allow for direct comparisons of these profiles across the 6 dis-
orders. This also facilitated our observation of the similarity
between shared differences in MRI-derived thickness and
genetic architecture across these 6 disorders, an observation
suggesting the presence of genetic variants that may be asso-
ciated with vulnerable brain phenotypes in common for the
6 disorders investigated here (Figure 2).
Virtual histology identified common cell-specific associa-
tions between ex vivo gene expression and in vivo MRI-
derived group differences in cortical thickness across the
34 cortical regions. In this analysis, all 6 disorders showed
a negative association with expression profiles specific to CA1
pyramidal cells. Regions with greater group differences in
cortical thickness are the regions with greater expression of
pyramidal (CA1-like) specific genes within the normative hu-
man brain, potentially indicating vulnerability of these re-
gions. Although the CA1 pyramidal-cell panel is labeled based
on the source of these cells (CA1 region of the hippocampus),
this does not mean that biologic processes implicated in CA1
genes are restricted to this region; in fact, similar molecular
processes are present throughout the human cerebral cortex
(see the eDiscussion in the Supplement for additional de-
tails). As such, we interpret the functional relevance of these
genes being associated with differences in cortical thickness.
It is important to state that the gene expression used through-
out this report comes from individuals without any diagno-
ses of neurologic or psychiatric disorders. Studies linking
cell-specific genes with psychiatric GWAS-associated genes
Figure 4. Principal Component 1 From the 6 Group Difference Profiles
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Figure 5. Trajectories of Expression for Genes Associated With the Shared Profile of Group Differences in Cortical Thickness
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the prenatal cluster (B) and postnatal cluster (C). Dot size (count) for
enrichment analysis (B,C) represents the number of genes that are within the
co-expression gene panels as well as a particular GO group (y-axis).
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show similar enrichment of CA1 pyramidal cells in ASD, BD, and
schizophrenia.42 This is another line of evidence linking geneti-
cally identified enrichment of CA1 pyramidal cells (previous
study42) with MRI-identified enrichment of CA1 pyramidal cells
within psychiatric disorders as seen in this study.
Principal component analysis identified a common com-
ponent of these cortical differences, indicating a shared inter-
regional profile of case-control differences in cortical thick-
ness among all 6 disorders. Although not the primary focus of
this report, we also report other PCs (explaining less vari-
ance); these appear to capture mostly disease-specific varia-
tions in group differences in cortical thickness (eFigure 3 in
the Supplement). As expected from the disease-specific analy-
ses, this PC1 profile was associated with the same 3 cell types,
namely CA1 pyramidal, astrocyte, and microglia. The CA1
pyramidal gene set is enriched with biologic processes re-
lated to dendritic arborization,27 and extensive dendritic
branching is a key morphologic phenotype of pyramidal
neurons.43 Similarly, our phenotype is derived from cortical
thickness, a measure that is directly associated with ex vivo
dendrite length across individuals (R2 = 0.25).44 Dendrites con-
trol the flow and integration of information within neurons and
are a medium of structural plasticity within the cerebral cor-
tex. Remodeling of dendritic trees and dendritic spines have
been observed as a result of environmental (stress and sen-
sory enrichment/deprivation) and genetic influences acting
both early and later in life.45,46 Alterations in dendritic mor-
phology, such as reduction in size of dendritic arborization,
have been described in postmortem samples from patients with
ASD,47,48 BD,49 schizophrenia,49 depression,50 and anxiety.50
The network of genes coexpressed with the CA1 pyrami-
dal genes associated with PC1 contained 2 clusters: one up-
regulated during the prenatal and the other during the post-
natal period. Through a series of bioinformatic approaches we
found evidence for 2 sets of processes involving cortical de-
velopment and cortical functioning, and, based on the tem-
poral profile, the influence of these processes prevails during
prenatal (prenatal cluster) and postnatal (postnatal cluster) life,
respectively. The emergence of these 2 clusters is highly con-
vergent with the 2-hit hypothesis regarding the etiology psy-
chiatric disorders, particularly with schizophrenia.51 We specu-
late that the group differences in cortical thickness observed
across the 6 psychiatric disorders are a summation of pro-
cesses occurring throughout life (prenatal and postnatal)
whereby atypical development and/or impaired cortical
functioning leave a morphological signature in the cerebral
cortex.
Prenatal/Neurodevelopmental Features
of Psychiatric Disorders
Thedevelopmentofthecerebralcortexduringgestationisacom-
plex process with a high susceptibility to perturbations. It is
hypothesized that the risk for psychiatric disorders increases
owing to perturbations in normal neurodevelopment.52,53 Cross-
disorder GWAS studies of ADHD, affective disorder, anorexia,
ASD, BD, and schizophrenia have all implicated genes involved
in regulating neurodevelopmental processes within radial glia
and interneurons of the developing neocortex.54
The prenatal (coexpression) cluster was enriched in neu-
rodevelopmental processes such as axonogenesis/guidance,
dendrite development, and, in general terms, neuron projec-
tion guidance. Axon guidance was also one of the key GO terms
found in the aforementioned cross-disorder GWAS study.54
Axon guidance is a process that directs growth cones to estab-
lish neuron pathways and cortical circuits. The strongest evi-
dence in implicating axon-guidance proteins in psychiatric
disorders is found in ASD whereby expression and GWAS stud-
ies converge on canonical axon-guidance proteins, such as
slits, robos, and semaphorins, all of which are present in
the PC1-CA1 coexpressed genes in our study (eFigure 11 in the
Supplement).55 See the eDiscussion in the Supplement regard-
ing subplate enrichment. We speculate that early changes in
neurodevelopmental processes may render certain regions and
cell types (pyramidal cells and their dendrites) more vulner-
able and, as such, more likely to be involved in the etiology of
all psychiatric disorders. This may explain the shared profile
of difference we observe.
Postnatal/Functional Features of Psychiatric Disorders
There is strong genetic, molecular, and histological evidence
demonstrating synaptic dysfunction and pathological changes
in spine density and morphology in psychiatric disorders
(particularly ASD, schizophrenia, MDD, and BD).56-59 Altera-
tions in these processes are likely to influence structural plas-
ticity and subsequent formation of complex and adaptable cir-
cuits. Both genetic and experience-dependent factors play a
role in structural plasticity across life, and a summation of these
factors may increase or decrease the risk of developing a psy-
chiatric disorder. These structural (dendritic spine) changes are
prominent during periods of maturation (childhood and youth),
coinciding with the peak age in incidence of psychiatric
disorders.56,60 The postnatal cluster of coexpressed genes was
enriched in synaptic transmission and regulation of synaptic
plasticity. We hypothesize that this cluster of genes is indica-
tive of plasticity-related morphological changes in the cere-
bral cortex that may in part reflect adverse experiences
common across all psychiatric disorders. This interpretation
is consistent with the fact that there are fewer disorder-
associated gene variants enriched in the postnatal cluster
as compared with the prenatal cluster, potentially indicating
that the postnatal processes are associated with environmen-
tal rather than genetic components of risk for psychiatric
disorders.
Limitations
There are several limitations to the approach used in this
report. First, only 2511 genes determined as having represen-
tative interregional profiles of their expression are used for
virtual histology. We chose this conservative approach given
that interregional profiles in case-control differences and
those in gene expression come from 2 different sets of brains
(see the eDiscussion in the Supplement for additional
details). This limitation may lower our ability to capture
other relevant neurobiologic signals. In an attempt to miti-
gate this limitation, downstream analyses use coexpression
to broaden the scope of the genes investigated, albeit indi-
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rectly. Second, we are using single-cell data from mice,
which have shown general conservation with human data.
However, there are some species-specific differences that
may not be accounted for in this report (see eMethods in the
Supplement for details on single-cell vs single-nucleus data
set).61 Third, our analysis uses a relatively coarse parcella-
tion allowing us to capture gross interregional patterns of
group differences in cortical thickness. This might, however,
increase the potential for missing subtle (vertex-level) varia-
tions. Lastly, when interpreting T1-weighted MRI, we
assume that these estimates reflect true variations in brain
phenotype rather than measurement error, artifacts, or other
physiological sources of T1 signal.
Conclusions
In summary, we characterized shared neurobiology across
6 psychiatric disorders that implicates pyramidal cells (and
dendrites) in representing a possible target of perturbations
that may increase a general vulnerability to mental illness. Our
bioinformatics-based analyses point toward involvement of
neurodevelopmental (prenatal) and plasticity-related (post-
natal) aspects underlying pathophysiology of psychiatric
disorders and their brain correlates. These shared aspects of
psychiatric disorders highlight the importance of transdiag-
nostic approaches in psychiatry.
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